Exclusive

Exclusive

Novartis may be close to settling a kickback case on the eve of a trial

By Ed Silverman

Vacuum tubes for blood analysis

Exclusive

New documents reveal Third Rock Ventures is set to launch a cancer diagnostics company

By Kate Sheridan

Exclusive

IBM halting sales of Watson AI tool for drug discovery amid sluggish growth

Great Hall of the People in Beijing

Exclusive

China creating national medical ethics committee to oversee high-risk clinical trials

By Jane Qiu

He Jiankui television screen cap

Exclusive

Chinese government funding may have been used for ‘CRISPR babies’ project, documents suggest

By Jane Qiu

Michael Deem photo illustration

Exclusive

American scientist played more active role in ‘CRISPR babies’ project than previously known

By Jane Qiu

Mitt Romney

Exclusive

Romney to speak before closed-door meeting of drug industry CEOs

By Nicholas Florko

Exclusive

In a sign of its concerns about Atul Gawande’s new venture, Optum sues over trade secrets

By Kate Sheridan and Casey Ross

Ginni Rometty CES

Exclusive

IBM isn’t retreating from using Watson in health care, CEO Rometty says

Exclusive

IBM Watson’s bet on China, a lucrative market for health business, starts to look shaky

By Casey Ross and Ike Swetlitz

NIH headquarters

Exclusive

Freeze on fetal tissue procurement may impede work at NIH cancer lab, agency says

By Ike Swetlitz

Cambridgeport

Exclusive

New documents shed light on secretive ElevateBio, next step for former Alexion execs

By Kate Sheridan

He Jiankui

Exclusive

Ethical issues plagued newly surfaced paper by ‘CRISPR babies’ scientist

By Sharon Begley

China Gene Edited Babies

Exclusive

‘CRISPR babies’ lab asked U.S. scientist for help to disable cholesterol gene in human embryos

By Sharon Begley

Genetic Frontiers Gene Edited Babies

Exclusive

UC Berkeley researcher, told of CRISPR’d baby study a year ago, warned scientist not to do it

By Rebecca Robbins

An embryo receives a small dose of Cas9 protein

Exclusive

He took a crash course in bioethics. Then he created CRISPR babies

By Sharon Begley

Driver app

Exclusive

‘We ran out of money’: High-profile startup seeking to connect patients with clinical trials shuts down

By Rebecca Robbins

Kratom

Exclusive

HHS recommended that the DEA make kratom a Schedule I drug, like LSD or heroin

By Ike Swetlitz

Exclusive

How an IBM Watson Health rescue mission collapsed — and a top executive was ousted

By Casey Ross and Ike Swetlitz

President Trump - New US-Mexico-Canada Trade Deal

Exclusive

In new document, the Trump administration labors to defend its latest drug pricing proposal

By Nicholas Florko

Congress Collage

Exclusive

Pharma’s ‘come-to-Jesus moment’: The industry braces for a Pelosi speakership and Democrats’ drug pricing agenda

Deborah DiSanzo

Exclusive

Head of IBM Watson Health leaving post after company stumbles, growing criticism

By Ike Swetlitz and Casey Ross

Stanton Glantz

Exclusive

UCSF settles sexual harassment suit involving star researcher

By Ivan Oransky and Adam Marcus

Ebola Congo vaccine

Exclusive

Ebola experts from CDC were pulled from outbreak zone amid security concern

By Helen Branswell

Brigham and Women's

Exclusive

Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research

By Ivan Oransky and Adam Marcus

UnitedHealth Group

Exclusive

Insurance giant, seizing on Trump initiative, will require Medicare beneficiaries to try controversial ‘step therapy’

By Ike Swetlitz

California Rent Control Initiative

Politics

In unlikely alliance, PhRMA sides with landlords in Calif. referendum on rent control

By Lev Facher and Rebecca Robbins

Moderna sign

Exclusive

Biotech unicorn Moderna prepares for sector’s biggest-ever IPO

By Damian Garde

Bana

Exclusive

For the first time, researchers will release genetically engineered mosquitoes in Africa

By Ike Swetlitz